<DOC>
	<DOCNO>NCT02107482</DOCNO>
	<brief_summary>The purpose study test effect localize narrow band ultraviolet ( NB-UVB ) phototherapy compare visible light produce UVB clearance psoriasis plaque resolution itch . Localized NB-UVB ( Levia® ) phototherapy device clear U.S Food Drug Administration ( FDA ) .</brief_summary>
	<brief_title>Use Localized NB-UVB ( Levia® ) Treatment Plaque-psoriasis</brief_title>
	<detailed_description>This ascend dose study treatment three time per week , initial treatment dose increase regimen adjust accord subject skin type . A suggested treatment regimen schedule provide Lerner Medical Devices , Inc : For subject skin type I : start dose 195 mj/cm2 , subject skin type II : start dose 330 mj/cm2 , subject skin type III : start dose 390 mj/cm2 , subject skin type IV : start dose 495 mj/cm2 , subject skin type V : start dose 525 mj/cm2 , subject skin type VI : start dose 600 mj/cm2 . The dose increase 15 % treatment , long side effect treatment burn redness .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Adults 18 year old bilateral psoriasis plaque , general good health determine Principal Investigator medical history physical exam . Able understand consent procedure Able comply protocol activity Must baseline symmetric target lesion baseline Target Lesion Score ( TLS ) 6 high ( scale 012 ) , i.e. , moderate intensity target . Target Lesion Scoring : Thickness , scale erythema plaque rat scale 04 . The three score sum . The minimum score 0 ; maximum 12 . Scores 6 great consider moderate severe . Patients le 18 year old Patients able understand consent procedure Patients unable comply protocol activity NonEnglish speaker : study assessments/questionnaires/evaluations scientifically validate language English Baseline target lesion score less 6 Patients photosensitive disorder medication demonstrate patient cause photosensitivity Patients receive concomitant phototherapy test sit Patient receive topical medication test site within 2 week study initiation Patient receive Methotrexate , Acitretin , Cyclosporine , oral medication psoriasis within 4 week study initiation Patients receive Etanercept ( Enbrel® ) within past 2 month study initiation Patients receive Infliximab ( Remicade® ) , Ustekinumab ( Stelara® ) , Golimumab ( Simponi® ) Adalimumab ( Humira® ) Alefacept ( Amevive® ) within past 3 month prior study initiation Receipt investigation agent within past 4 week ( within 5 half life ) prior study ignition Systemic corticosteroid therapy within past month Concurrent use prohibit medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>